Management of HPV‑Negative Abnormal Cytology in Women ≥ 60 Years
Continuation of Screening After Age 65
Risk Associated with HPV‑Negative ASC‑US
Limitations of Colposcopy
Indications for Referral to Colposcopy
Cervical Cancer Screening Guidelines for Women with LSIL/ASCUS History
Screening Intervals
- The American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology recommend that women with a history of LSIL or ASCUS with negative HPV testing undergo cotesting (HPV + Pap) at 3-year intervals, rather than 5-year HPV screening intervals, due to a higher risk of CIN3+ 5, 6, 7
- The 5-year risk of CIN3+ after HPV-negative ASCUS is 1.1%, which is significantly higher than after negative cotesting (0.27%), according to the Kaiser Permanente Northern California cohort data 5, 6
- Women with prior ASCUS/LSIL abnormalities require more frequent surveillance even after achieving negative HPV results, as stated by the ASCCP consensus conference 5, 6, 7
Risk Stratification
- Negative cotesting (HPV-/Pap-): 0.27% 5-year risk of CIN3+, which qualifies for 5-year intervals 8
- HPV-negative ASCUS: 1.1% 5-year risk of CIN3+, which requires 3-year intervals 5, 6
Discontinuation of Screening
- A woman with a history of LSIL or ASCUS cannot discontinue screening at age 65 based on an HPV-negative ASCUS or LSIL result alone, and must achieve either 2 consecutive negative cotests or 3 consecutive negative Pap tests before discontinuing screening 5, 6, 7
- The ASCCP guidelines recommend continued enhanced surveillance with 3-year cotesting until adequate negative screening history is established, even after a negative colposcopy and subsequent negative tests 5, 6
Management of HPV‑Negative LSIL in Women Aged ≥ 65 Years
Screening Continuation Criteria
- Women ≥ 65 years with any prior abnormal cytology (including LSIL) must continue cervical cancer screening even when the HPV test is negative; discontinuation is allowed only after establishing an adequate negative screening history (e.g., two consecutive negative cotests or three consecutive negative Pap tests, with the most recent test performed within the prior 5 years)【9】.
- The NCCN guidelines (2014) recommend maintaining enhanced surveillance (cotesting every 3 years) until the required negative history is achieved, rather than reverting to routine 5‑year intervals【9】.
Immediate Management Recommendations
- Do not perform colposcopy immediately for an HPV‑negative LSIL result unless a visible cervical lesion is identified on examination【10】.
- Repeat cotesting (Pap + HPV) in 1 year rather than returning to the standard 5‑year screening schedule【10】.
Follow‑Up Based Decision Pathway
- If the repeat cotest shows any cytologic abnormality (ASC‑US or higher) or a positive HPV result, refer the patient promptly to colposcopy【10】.
- If the repeat cotest is negative for both cytology and HPV, continue enhanced surveillance with cotesting every 3 years until the criteria for discontinuation are met【9】.
Rationale for Deferring Immediate Colposcopy
- The absolute risk of CIN 3+ after an HPV‑negative LSIL is low (≈0.5–1 %) and does not reach the threshold that mandates immediate colposcopic evaluation, unlike higher‑grade cytology results (e.g., HSIL, ASC‑H)【10】.
- Colposcopy has limited sensitivity for detecting all cervical lesions; a negative colposcopic exam would not eliminate the need for continued surveillance in this age group【10】.
Documentation and Patient Counseling
- Document that the patient has not satisfied NCCN criteria for screening discontinuation and therefore requires ongoing surveillance【9】.
- Counsel the patient that screening will continue beyond age 65 until the required series of negative cotests (or Pap tests) is completed, emphasizing the importance of adherence to follow‑up appointments【9】.